



Fax Referral To: 800-323-2445
Phone: 866-278-6634

Gilenya® (fingolimod)
Enrollment Form
For Blue Cross Blue Shield of Rhode Island Members

Date: _____ Needs by Date (Please Specify): _____

Ship to: Patient Office Other: _____

PATIENT INFORMATION

(Complete the following or send patient demographic sheet)

Patient Name: _____
Address: _____
City, State, Zip: _____
Home Phone: _____
Alternate Phone: _____
SS #: _____
Insurance ID: _____
Date of Birth: _____ Gender: _____

PRESCRIBER INFORMATION

Prescriber's Name: _____
State License #: _____ UPIN: _____
DEA #: _____ NPI #: _____
Group or Hospital: _____
Address: _____
City, State Zip: _____
Phone: _____ Fax: _____
Contact Person: _____
Contact Phone: _____

INSURANCE INFORMATION (Please copy and attach the front and back of insurance and prescription drug card)

Prescription Card: Name of Insurer: _____ ID#: _____ BIN: _____ PCN: _____ Group: _____
Primary Insurance: Subscriber: _____ ID#: _____ Name of Insurer: **Blue Cross Blue Shield of RI** Phone: _____
Secondary Insurance: Subscriber: _____ ID#: _____ Name of Insurer: _____ Phone: _____

STATEMENT OF MEDICAL NECESSITY for BCBS of Rhode Island Members

Diagnosis (ICD-9 code): 340 Multiple Sclerosis Other: _____ • Date of Diagnosis: _____

APPROVAL CRITERIA: CHECK ALL BOXES THAT APPLY.

NOTE: Any areas not filled out are considered not applicable to your patient & MAY AFFECT THE OUTCOME of this request.

- Patient diagnosis is Multiple Sclerosis Yes No
- Patient has relapsing form of MS Yes No
- Patient will receive Gilenya concurrently with antineoplastic, immunosuppressive or immune modulating therapy? Yes No
- Patient will receive Gilenya concurrently with a biologic agent for MS Yes No
- Patient has had the following tests performed within 6 months prior to starting Gilenya therapy with normal results
 Electrocardiogram (ECG) Complete blood count (CBC) Liver function tests (LFTs)
- Patient has a history of diabetes or uveitis Yes No
If Yes, was an ophthalmologic exam performed within 6 months prior to starting Gilenya therapy Yes No
- Patient has a history of chickenpox Yes No
If No, was the patient vaccinated against varicella zoster virus (VZV) Yes No
If No, was immunity to varicella confirmed with VZV antibody testing Yes No
- Will (was) patients first dose of Gilenya administered under health care provider supervision Yes No
- Patient was observed for a minimum of 6 hours following the first dose of Gilenya for signs/symptoms of bradycardia Yes No

PRESCRIPTION INFORMATION

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
<input type="checkbox"/> Gilenya (fingolimod)				

X
PRODUCT SUBSTITUTION PERMITTED (Date)

X
DISPENSE AS WRITTEN (Date)